AstraZeneca Signs Deal with Allergan for Up To $1.52 Billion
03 October 2016 - 5:53PM
Dow Jones News
LONDON--AstraZeneca PLC (AZN.LN) said on Monday that it has
signed a deal with Allergan PLC (AGN) worth up to $1.52 billion
through its global biologics research and development unit.
The bio-pharmaceutical company said that under the deal,
Allergan will have the global rights to an antibody for Crohn's
disease.
Allergan will pay upfront $250 million, but it may also make
some payments to AstraZeneca worth up to $1.27 billion, depending
on how good the sales of the antibody are, the company said.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
October 03, 2016 02:38 ET (06:38 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
